Published in Am Rev Respir Dis on September 01, 1985
Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev (1991) 7.12
Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest (1992) 2.62
Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis. J Clin Microbiol (1987) 2.59
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med (2012) 2.01
Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev (2010) 1.97
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr (2008) 1.96
Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest (1990) 1.66
Purification and characterization of an active fragment of the LasA protein from Pseudomonas aeruginosa: enhancement of elastase activity. J Bacteriol (1990) 1.57
Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc (2007) 1.49
Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest (1989) 1.44
Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun (1993) 1.40
Airway remodelling in children with cystic fibrosis. Thorax (2007) 1.38
Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax (1991) 1.30
Elastin and the lung. Thorax (1986) 1.24
Pseudomonas and neutrophil products modify transferrin and lactoferrin to create conditions that favor hydroxyl radical formation. J Clin Invest (1991) 1.20
The Pseudomonas aeruginosa secretory product pyocyanin inactivates alpha1 protease inhibitor: implications for the pathogenesis of cystic fibrosis lung disease. Infect Immun (1999) 1.20
Protease cleavage of iron-transferrin augments pyocyanin-mediated endothelial cell injury via promotion of hydroxyl radical formation. Infect Immun (1996) 1.09
Lung infections. 3. Pseudomonas aeruginosa and other related species. Thorax (1998) 1.08
Pseudomonas aeruginosa antibodies in blood spots from patients with cystic fibrosis. Arch Dis Child (1989) 1.06
Proteolysis of surfactant protein D by cystic fibrosis relevant proteases. Lung (2003) 1.03
Kinetics of proteolysis of hog gastric mucin by human neutrophil elastase and by Pseudomonas aeruginosa elastase. Infect Immun (1988) 1.02
Genotyping of Pseudomonas aeruginosa sputum and stool isolates from cystic fibrosis patients: evidence for intestinal colonization and spreading into toilets. Epidemiol Infect (1989) 0.99
Protease-cleaved iron-transferrin augments oxidant-mediated endothelial cell injury via hydroxyl radical formation. J Clin Invest (1995) 0.99
The role of collagenase in emphysema. Respir Res (2001) 0.96
Development of an integrated metabolomic profiling approach for infectious diseases research. Analyst (2011) 0.92
Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros (2005) 0.88
Porins of Pseudomonas aeruginosa induce release of tumor necrosis factor alpha and interleukin-6 by human leukocytes. Infect Immun (1997) 0.88
Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis. Chest (2009) 0.86
Pathogenesis and management of lung disease in cystic fibrosis. J R Soc Med (1991) 0.85
Cystic fibrosis in adults. From researcher to practitioner. West J Med (1996) 0.84
Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child (1994) 0.84
Disruption of respiratory cilia by proteases including those of Pseudomonas aeruginosa. Infect Immun (1986) 0.82
Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation. Pediatr Pulmonol (2012) 0.82
Automated CT scan scores of bronchiectasis and air trapping in cystic fibrosis. Chest (2014) 0.81
Increased elastase secretion by peripheral blood monocytes in cystic fibrosis patients. Clin Exp Immunol (1990) 0.81
JAK/STAT regulation of Aspergillus fumigatus corneal infections and IL-6/23-stimulated neutrophil, IL-17, elastase, and MMP9 activity. J Leukoc Biol (2016) 0.76
Novel end points for clinical trials in young children with cystic fibrosis. Expert Rev Respir Med (2013) 0.75
Corticosteroid treatment in cystic fibrosis. Arch Dis Child (1993) 0.75
Cellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosa. Toxins (Basel) (2016) 0.75
Myeloperoxidase and eosinophil cationic protein in serum and sputum during antibiotic treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection. Mediators Inflamm (1995) 0.75
Neutrophil necrosis and annexin 1 degradation associated with airway inflammation in lung transplant recipients with cystic fibrosis. BMC Pulm Med (2012) 0.75
Collagen degrading activity associated with Mycobacterium species. Thorax (1999) 0.75
Labeling of proteins by reductive methylation using sodium cyanoborohydride. J Biol Chem (1979) 5.42
Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet (1990) 4.39
Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis (1985) 3.71
Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet (1993) 3.17
Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis (1979) 3.02
Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest (1987) 2.97
Acute pulmonary hemorrhage in infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med (1998) 2.90
Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay. J Infect Dis (1978) 2.60
Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis (1983) 2.41
Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology. J Pediatr (1986) 2.38
Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry (1992) 2.38
Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans R Soc Trop Med Hyg (2001) 2.34
Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet (2000) 2.26
Pneumothorax in cystic fibrosis: a 26-year experience. Ann Thorac Surg (1989) 2.23
The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol (2001) 2.18
Cardiopulmonary pathology in patients with sleep apnea/obesity hypoventilation syndrome. Hum Pathol (1997) 2.12
Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis (1986) 2.10
Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med (1976) 2.04
The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol (1983) 1.88
Course of cystic fibrosis in 95 patients. J Pediatr (1976) 1.78
Protein labeling by reductive alkylation. Methods Enzymol (1983) 1.74
Purification and characterization of an extracellular protease from Pseudomonas cepacia. Infect Immun (1989) 1.70
Infection with a plasmid-free variant Chlamydia related to Chlamydia trachomatis identified by using multiple assays for nucleic acid detection. J Clin Microbiol (1992) 1.66
Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis (1995) 1.63
Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Infect Dis (1985) 1.61
Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr (1994) 1.61
The effect of early diagnosis and treatment in cystic fibrosis: a seven-year study of 16 sibling pairs. Am J Dis Child (1977) 1.55
Restoration of in-vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet (1975) 1.50
Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr (1984) 1.47
Lymphocyte responsiveness to Pseudomonas aeruginosa in cystic fibrosis: Relationship to status of pulmonary disease in sibling pairs. J Pediatr (1978) 1.45
Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest (1989) 1.44
In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis. Antimicrob Agents Chemother (1984) 1.41
Granulocyte transfusions in septic adult and newborn rats: distribution of granulocytes and effect on peripheral blood and bone marrow. J Lab Clin Med (1990) 1.40
Morphometric analysis of the lung in bronchopulmonary dysplasia. Am Rev Respir Dis (1991) 1.40
A new colorimetric nucleic acid hybridization assay for Listeria in foods. Int J Food Microbiol (1989) 1.39
Pulmonary intralobar sequestration in a patient with cystic fibrosis. Hum Pathol (1997) 1.38
Surfactant protein deficiency in familial interstitial lung disease. J Pediatr (2001) 1.37
Weight and menstrual function in patients with eating disorders and cystic fibrosis. Pediatrics (1990) 1.37
In vitro inhibition of lymphocyte proliferation by Pseudomonas aeruginosa phenazine pigments. Infect Immun (1983) 1.36
Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages. Pediatr Res (1979) 1.36
Symptomatic hepatic disease in cystic fibrosis: incidence, course, and outcome of portal systemic hunting. Gastroenterology (1976) 1.32
Nontuberculous mycobacteria in cystic fibrosis. An autopsy study. Am J Respir Crit Care Med (1996) 1.29
Cellular immunity to bacteria: impairment of in vitro lymphocyte responses to Pseudomonas aeruginosa in cystic fibrosis patients. Infect Immun (1977) 1.29
13C NMR studies of ribonuclease A methylated with [13C]Formaldehyde. J Biol Chem (1979) 1.28
Studies on the mechanism of T cell inhibition by the Pseudomonas aeruginosa phenazine pigment pyocyanine. J Immunol (1987) 1.27
Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol (1998) 1.26
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother (2001) 1.25
Exercise conditioning and cardiopulmonary fitness in cystic fibrosis. The effects of a three-month supervised running program. Chest (1981) 1.25
Impaired surface membrane expression of C3bi but not C3b receptors on neonatal neutrophils. Pediatr Res (1987) 1.22
Ultrastructure and function of alveolar macrophages from cystic fibrosis patients. Pediatr Res (1980) 1.22
Bronchial artery embolization to control hemoptysis in cystic fibrosis. Radiology (1990) 1.20
Benign endobronchial mesenchymal tumors: their relationship to parenchymal pulmonary hamartomas. Am J Surg Pathol (1982) 1.18
Bronchopulmonary dysplasia: a morphometric study with emphasis on the pulmonary vasculature. Pediatr Pathol (1984) 1.17
Lipophosphonoglycan of the plasma membrance of Acanthamoeba castellanii. Isolation from whole amoebae and identification of the water-soluble products of acid hydrolysis. J Biol Chem (1974) 1.15
Treatment and prognosis of massive hemoptysis in cystic fibrosis. Am Rev Respir Dis (1978) 1.15
Hemolysis, toxicity, and randomly amplified polymorphic DNA analysis of Stachybotrys chartarum strains. Appl Environ Microbiol (1999) 1.15
Open thoracotomy for pneumothorax in cystic fibrosis. Am Rev Respir Dis (1975) 1.15
Proteinases of Pseudomonas aeruginosa evoke mucin release by tracheal epithelium. J Clin Invest (1984) 1.14
Defective cellular immunity to gram-negative bacteria in cystic fibrosis patients. Infect Immun (1979) 1.14
Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother (1983) 1.12
Q-beta replicase-amplified assay for detection of Mycobacterium tuberculosis directly from clinical specimens. J Clin Microbiol (1995) 1.12
Phosphonoglycan. A major polysaccharide constituent of the amoeba plasma membrane contains 2-aminoethylphosphonic acid and 1-hydroxy-2-aminoethylphosphonic acid. J Biol Chem (1973) 1.12
Intramolecular interactions of amino groups in 13C reductively methylated hen egg-white lysozyme. J Biol Chem (1982) 1.09
Course of cystic fibrosis in black patients. J Pediatr (1976) 1.09
Linkage of DNA markers to cystic fibrosis in 26 families. Am J Hum Genet (1986) 1.09
Cystic fibrosis in young adults: an overlooked diagnosis, with emphasis on pulmonary function and radiological patterns. Chest (1970) 1.09
Treatment and prognosis of rectal prolapse in cystic fibrosis. Gastroenterology (1982) 1.06
Timing of referral for lung transplantation for cystic fibrosis: overemphasis on FEV1 may adversely affect overall survival. Chest (1999) 1.05
Sequence homologies between nucleotide binding regions of CFTR and G-proteins suggest structural and functional similarities. FEBS Lett (1995) 1.05
Performance of an automated Q-beta replicase amplification assay for Mycobacterium tuberculosis in a clinical trial. J Clin Microbiol (1997) 1.05
The pathology of fungal infection and colonization in patients with cystic fibrosis. Hum Pathol (1989) 1.04
In vitro effect of synthetic pyocyanine on neutrophil superoxide production. Infect Immun (1987) 1.04
[13C]Methylated ribonuclease A. 13C NMR studies of the interaction of lysine 41 with active site ligands. J Biol Chem (1981) 1.04
Pathophysiologic basis for symptomatic treatment of fever. Pediatrics (1977) 1.04
Risk factors for the degradation of lung elastic fibers in the ventilated neonate. Implications for impaired lung development in bronchopulmonary dysplasia. Am Rev Respir Dis (1992) 1.04
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr (1984) 1.04
Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr (1986) 1.03
Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. J Clin Invest (1976) 1.03
Regional distribution of macroscopic lung disease in cystic fibrosis. Am Rev Respir Dis (1986) 1.03
Obstructive azoospermia as a diagnostic criterion for the cystic fibrosis syndrome. Lancet (1982) 1.02
Kinetics of proteolysis of hog gastric mucin by human neutrophil elastase and by Pseudomonas aeruginosa elastase. Infect Immun (1988) 1.02
Environmental risk factors associated with pediatric idiopathic pulmonary hemorrhage and hemosiderosis in a Cleveland community. Pediatrics (1997) 1.02
Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. AIDS (1997) 1.01
Evaluation of Stachybotrys chartarum in the house of an infant with pulmonary hemorrhage: quantitative assessment before, during, and after remediation. J Urban Health (2000) 1.01
The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg (1990) 1.00
Treatment and prognosis of lobar and segmental atelectasis in cystic fibrosis. Am Rev Respir Dis (1978) 1.00
The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol (1980) 0.98
Beta adrenergic receptors in lymphocytes and granulocytes from patients with cystic fibrosis. J Clin Invest (1983) 0.98
Cystic fibrosis care-further considerations. Arch Dis Child (1972) 0.98
Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis. Pediatr Pulmonol (1991) 0.97
Halothane inhibits two components of calcium current in clonal (GH3) pituitary cells. J Neurosci (1991) 0.97